One of the recent studies investigated the sodium-glucose cotransporter-2 inhibitors (SGLT2i) as a co-therapy with GLP-1 RAs for treating type II diabetes mellitus [51]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.